DUBLIN—During Allergan’s (NYSE: AGN) conference call with investors earlier this week, Brent Saunders, the company’s president and CEO, announced “a streamlined executive team to lead Allergan going forward.”

Saunders said, “I have been carefully considering how to streamline our management structure to better align our resources as a focused branded Growth Pharma business with many leading global brands. In this new leadership structure, all of our commercial businesses will be combined under Bill Meury, who has been appointed our chief commercial officer.” Previously, Meury had served as Allergan’s executive vice president and president, Branded Pharma.

Saunders also announced the appointment of Rob Stewart to the position of chief operating officer. “In this role, Rob will make sure our manufacturing operations run smoothly to meet our sales goals, oversee harmonization of our IT systems and processes, and finish previous integrations,” he said.

There will be three major business segments under Meury. The first segment is U.S. Specialized Therapeutics, which includes eyecare, medical aesthetics, medical dermatology, and Botox Therapeutic. The second segment is U.S. General Medicine, which includes CNS, CV, GI, women's health, AI, and urology. The third segment is International, which includes all of Allergan’s businesses outside the U.S., organized in multiple regions. Anda, Allergan’s fourth segment, will continue to report to Rob Stewart.

“I believe this new commercial structure will further enhance our global focus, speed decision-making, and align resources and priorities with our R&D priorities,” Saunders said.